Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

BeiGene, Ltd. (ONC) reported $1.12 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 48.6%. EPS of $1.22 for the same period compares to -$2.41 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.12 billion, representing a surprise of -0.65%. The company delivered an EPS surprise of +271.83%, with the consensus EPS estimate being -$0.71.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how BeiGene performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product revenue, net: $1.11 billion versus $1.12 billion estimated by four analysts on average. Product Revenue- BRUKINSA(Zanubrutinib): $791.66 million versus the four-analyst average estimate of $820.07 million. Product Revenue- Tislelizumab: $171.16 million versus $171.33 million estimated by four analysts on average. Product Revenue- XGEVA: $70.42 million versus the three-analyst average estimate of $56.55 million. Product Revenue- Other: $17.90 million compared to the $14.28 million average estimate based on three analysts. Product Revenue- POBEVCY: $13.75 million versus the three-analyst average estimate of $16.11 million. Product Revenue- BLINCYTO: $23.91 million versus $20.42 million estimated by three analysts on average. Product Revenue- KYPROLIS: $19.73 million versus the three-analyst average estimate of $16.51 million. Collaboration revenue: $8.75 million compared to the $6.49 million average estimate based on two analysts. View all Key Company Metrics for BeiGene here>>>Shares of BeiGene have returned +15.4% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BeiGene, Ltd. (ONC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks